Bausch+Lomb Results Presentation Deck
NOV03¹: FDA Accepted NDA
PDUFA Date
June 2023
Current Market
BAUSCH + LOMB
+ Investigational first in class treatment for Dry Eye Disease (DED) associated with
Meibomian Gland Dysfunction (MGD)
+
+
Consistent statistically significant efficacy, safety and tolerability have now
been demonstrated in two Phase 3 studies of NOV03¹ and one Phase 2 study
•. DED is one of the most common ocular surface disorders,
with approximately 18M Americans diagnosed with DED.2,3
Statistically significant difference of sign and symptom was noted at day 15
and 57 in both Phase 3 studies
• In one study, it was found that ~90% of patients with DED
had MGD involvement.4
2023 LAUNCH7
U.S. Prescription Dry Eye Market Growth
-24%
CAGR
2016-20215
1. In 2019, the Company acquired an exclusive license from Novaliq GmbH for the commercialization and development of NOV03 in the United States and Canada.
2. Leonardi, A., Modugno, R. L., & Salami, E. (2021). Allergy and Dry Eye Disease. Ocular immunology and inflammation, 29(6), 1168-1176. https://doi.org/10.1080/09273948.2020.1841804.
3. 2020 Dry Eye Products Market Report: A global Analysis for 2019 to 2025. Market Scope. Retrieved from https://www.market-scope.com/pages/reports/250/2020-ophthalmic-landscape-report-global-analysis-for-2019-to-2025-april-2021#reports.
4. Badian RA. Sci Rep. 2021:11:23412.; Lemp MA, et al. Cornea. 2012:31:472-478. Messmer EM. Dtsch Arztebl Int. 2015:112(5):71-81.
5. IQVIA NSP.
6. Clarivate
7. See Slide 1 for further information on forward-looking statements.
Expect Double
Digit Growth
2021-20276,7
19View entire presentation